Matteo Lazzeroni, Matteo Puntoni, Aliana Guerrieri-Gonzaga, Davide Serrano, Luca Boni, Tania Buttiron Webber, Marianna Fava, Irene M Briata, Livia Giordano, Maria Digennaro, Laura Cortesi, Fabio Falcini, Patrizia Serra, Franca Avino, Francesco Millo, Katia Cagossi, Elisa Gallerani, Alessia De Simone, Anna Cariello, Giuseppe Aprile, Maria Renne, Bernardo Bonanni, Andrea DeCensi
PURPOSE: Five-year data of the phase III trial TAM-01 showed that low-dose tamoxifen at 5 mg once daily administered for 3 years in women with intraepithelial neoplasia (IEN) reduced by 52% the recurrence of invasive breast cancer or ductal carcinoma in situ (DCIS), without additional adverse events over placebo. Here, we present the 10-year results. METHODS: We randomly assigned 500 women with breast IEN (atypical ductal hyperplasia, lobular carcinoma in situ [LCIS], or hormone-sensitive or unknown DCIS) to low-dose tamoxifen or placebo after surgery with or without irradiation...
June 10, 2023: Journal of Clinical Oncology